Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Published

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal
Journal of psychopharmacology (Oxford, England)
Date
2016-12-01
Source
PubMed
DOI
10.1177/0269881116675512
PubMed
27909164

Authors

Ross SBossis AGuss JAgin-Liebes GMalone TCohen BMennenga SEBelser AKalliontzi KBabb JSu ZCorby PSchmidt BL
Watch author

Derived topics and classifications

psilocybin DepressionAnxietyEnd-of-Life DistressWellbeingSpiritualityMystical ExperienceRandomized Controlled TrialCancer Patients Randomized Controlled Trial

Citation graph

0 referenced DOIs found in stored source metadata. 20 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurement2026-12-01Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery model2026-12-01Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression2026-11-01Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD2026-09-08Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)2026-08-12Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosis2026-07-20Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview2026-07-13Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventions2026-07-03Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders2026-07-01Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats2026-07-01Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex2026-06-28Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation2026-06-03Psilocybin: Chemical Foundations and Emerging Therapeutic Potential2026-06-01Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations2026-06-01Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis2026-05-29Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression2026-05-15Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of Care2026-05-14Psilocybin in the Treatment of Cocaine Use Disorder2026-05-07Human brain changes after first psilocybin use2026-05-05Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine2026-05-01

Related papers

Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding StudyClinicalTrials.gov · 2023-03-20The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy AdultsClinicalTrials.gov · 2026-09-02Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult VolunteersClinicalTrials.gov · 2023-05-19Consciousness and Psilocybin Effects on Well-Being: The CoPEWell StudyClinicalTrials.gov · 2026-09-29Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of PsilocybinClinicalTrials.gov · 2026-07-29Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-samplingClinicalTrials.gov · 2026-06-05Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot PhaseClinicalTrials.gov · 2025-05-16Safety for Home Administration of Microdose Psilocybin UseClinicalTrials.gov · 2026-08-14